Prolactin-blocking drugs may play a role in reversing or preventing post-partum cardiomyopathy (PPCM), according to US research. Studies in mice showed that those that lacked the gene STAT3, specifically in heart muscle cells, consistently developed PPCM. The researchers then found a similar imbalance in humans. However, prolactin-blocking drugs were found to overcome the heart damage caused by a lack of the gene STAT3. Women with PPCM who were given prolactin-blocking drugs showed an increased heart function and all survived the four-month observation period (Cell Online 2007).
Have you registered with us yet?
Register now to enjoy more articles and free email bulletins